DB17075InvestigationalGene Therapies
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in... It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the aspartoacylase enzyme (ASPA).
- Also known as
- rAAV-Olig001-ASPA
- Code names
- MYR-101
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of MYR-101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account